Array Strikes New Deal For Cancer Drug With Longtime Partner Genentech, Taking $28M Upfront
This article was originally published in The Pink Sheet Daily
Executive Summary
Genentech gains a second compound that regulates cell cycle progression and Array receives cash to advance four in-house drugs through the clinic.
You may also be interested in...
Deal Watch: Teva/Mylan/Perrigo Speculation Pushes Busy Celgene, AstraZeneca Offstage
AstraZeneca and its large-molecule affiliate MedImmune will partner with Celgene to develop anti-PD-LI immune checkpoint inhibitor MEDI4736. MedImmune also signed combination trial agreements with Juno and Immunocore, while Celgene arranged to buy Quanticel and Mesoblast.
Gilead Takes Calistoga To Boost Cancer Effort
Gilead Sciences Inc.’s recent acquisition of Calistoga Pharmaceuticals Inc. for $375 million up front is the richest deal yet for PI3K inhibitors, an emerging class of cancer drugs that many companies large and small are hotly pursuing.
Array Biopharma Wins Two Important Deals In Six Months, But Wall Street Shrugs
To management's frustration, the biotech's deals with Novartis and Amgen haven't helped its market cap, one more sign that validating deals with Big Pharma don't move investors.